Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06414954 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

A Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK, sponsored by NMD Pharma A/S.

Recruiting
Registry status
Phase 2
Development phase
84
Enrollment target
20
Study locations

NCT06414954 is a Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK that is actively recruiting participants, run by NMD Pharma A/S. The registered enrollment target is 84 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06414954, a Phase 2 study of Myasthenia Gravis and Myasthenia Gravis, MuSK, is actively recruiting participants, sponsored by NMD Pharma A/S.

RECRUITING
Registry status
Phase 2
Development phase
84 participants
Enrollment target
20
Study locations

Study Summary

This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

Conditions Studied

Myasthenia Gravis Myasthenia Gravis, MuSK

Interventions

  • DRUG Placebo
  • DRUG NMD670

Study Locations (20)

Other

  • UZ Leuven - Leuven
  • Aarhus University Hospital - Aarhus
  • Rigshospitalet University of Copenhagen - Copenhagen
  • Centre de référence des maladies neuromusculaires AOC-CHU de Bordeaux - Hôpital Pellegrin - Bordeaux
  • Centre de Référence des Maladies Neuromusculaires et de la SLA - Marseille
  • Centre Hospitalier Universitaire de Nantes - Hôtel Dieu Centre de Référence des Maladies Neuromusculaires Rares - - Nantes
  • CHU de Nice - Nice
  • Unité de Recherche Clinique NeuroSciences - Nice
  • JSC Curatio - Tbilisi

California

  • Profound Research LLC - Carlsbad
  • University of California Irvine Medical Center - Irvine

Florida

  • SFM Clinical Research, LLC - Boca Raton
  • Neuromuscular Research Division | University of South Florida - Tampa

Colorado

  • University of Colorado Neuromuscular Division - Aurora

Georgia

  • Augusta University, Neuroscience Center - Augusta

Missouri

  • NextGen Precision Health - Columbia

North Carolina

  • The University of North Carolina at Chapel Hill - Chapel Hill

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2024-05-16
Est. Completion 2026-05
Phase Phase 2

Sponsor

NMD Pharma A/S

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06414954

The ClinicalTrials.gov registry entry for NCT06414954 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (56% lower). The listed sponsor is NMD Pharma A/S, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06414954 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06414954 about?

NCT06414954 is a clinical study titled "Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis". This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.

What is the current status of trial NCT06414954?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2024-05-16. Estimated completion is 2026-05.

What conditions does trial NCT06414954 study?

This clinical trial studies the following conditions: Myasthenia Gravis, Myasthenia Gravis, MuSK.

What interventions are being tested in trial NCT06414954?

The interventions under investigation include: Placebo (DRUG), NMD670 (DRUG).

Who is sponsoring clinical trial NCT06414954?

This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06414954 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myasthenia Gravis

All registered trials for this condition

Myasthenia Gravis, MuSK

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.